PRCT (PROCEPT BioRobotics) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $20.85
GF Value $91.98
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

PROCEPT BioRobotics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

PRCT vs ALMR, AHCO, ENOV: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Devices subindustry, PROCEPT BioRobotics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PROCEPT BioRobotics Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Margin of Safety % (DCF FCF Based) falls into.


PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.85
Price
$91.98
GF Value